Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
General Counsel Anderman repurchases CMPX shares at 15-month lows; repeat buyer with perfect timing on prior trade.
Jonathan Anderman, the company's General Counsel, is making his second open-market purchase of CMPX shares in 36 months, adding materially to his stake at a point when the stock trades well below its 52-week high. The timing is noteworthy: his prior open-market purchase last year generated strong gains within months, demonstrating he has executed well-timed purchases at this company before. This current buy occurs as the stock sits near its 52-week low following a sharp decline, positioning the trade as a bet on recovery from deeply depressed prices. However, the company remains unprofitable with zero revenue, operating at a significant cash burn, which means Anderman is buying into fundamental weakness—not filling a cyclical dip in an otherwise healthy business. His willingness to deploy capital despite these deteriorating fundamentals is the core signal: either he has visibility into a near-term inflection point that is not yet reflected in the financials, or he is accumulating on weakness believing long-term value exists at these prices.
Gen Counsel Jonathan Anderman bought 20,000 CMPX shares at $1.54; holdings surge 2000.0% to 21,000 shares amid -40.9% 30-day decline.
Jonathan Anderman, General Counsel & Corporate Secretary, purchased 20,000 shares at $1.54 on 2025-04-07, increasing his holdings from 1,000 to 21,000 shares. The transaction size—a 2000.0% increase in his prior holdings—represents a substantial personal commitment by a senior officer at a critical juncture: the stock has declined 40.9% over the preceding 30 days and trades 59.2% below its 52-week high of $3.90. The company reported $0.00 revenue in its latest quarter and a $-10.5M net loss over the most recent full fiscal year, indicating ongoing operational losses. The magnitude of this buy by a C-suite executive and the timing relative to steep near-term price deterioration create noteworthy material for investor scrutiny, though the underlying fundamentals (unprofitable operations, zero current revenue) represent the core risk independent of this transaction.
